Jones Financial Companies’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12M | Buy |
223,097
+70,725
| +46% | +$3.83M | 0.01% | 764 |
|
|
2025
Q4 | $7.47M | Buy |
152,372
+23,629
| +18% | +$1.1M | ﹤0.01% | 522 |
|
|
2025
Q3 | $5.14M | Buy |
128,743
+13,795
| +12% | +$539K | ﹤0.01% | 561 |
|
|
2025
Q2 | $4.43M | Buy |
114,948
+20,560
| +22% | +$786K | ﹤0.01% | 529 |
|
|
2025
Q1 | $3.66M | Buy |
94,388
+21,953
| +30% | +$804K | ﹤0.01% | 499 |
|
|
2024
Q4 | $2.45M | Buy |
72,435
+16,185
| +29% | +$583K | ﹤0.01% | 510 |
|
|
2024
Q3 | $2.29M | Buy |
56,250
+32,916
| +141% | +$1.35M | ﹤0.01% | 429 |
|
|
2024
Q2 | $898K | Buy |
23,334
+21,172
| +979% | +$891K | ﹤0.01% | 442 |
|
|
2024
Q1 | $92.7K | Buy |
2,162
+529
| +32% | +$21.8K | ﹤0.01% | 610 |
|
|
2023
Q4 | $60.5K | Buy |
1,633
+306
| +23% | +$11K | ﹤0.01% | 443 |
|
|
2023
Q3 | $48.1K | Buy |
1,327
+509
| +62% | +$18.1K | ﹤0.01% | 370 |
|
|
2023
Q2 | $29.2K | Sell |
818
-240
| -23% | -$8.61K | ﹤0.01% | 395 |
|
|
2023
Q1 | $37.6K | Buy |
1,058
+240
| +29% | +$8.4K | ﹤0.01% | 374 |
|
|
2022
Q4 | $29K | Buy |
+818
| New | +$27.2K | ﹤0.01% | 378 |
|
|
2022
Q3 | – | Sell |
-1,124
| Closed | -$61K | – | 610 |
|
|
2022
Q2 | $61K | Sell |
1,124
-418
| -27% | -$23.1K | ﹤0.01% | 324 |
|
|
2022
Q1 | $84K | Buy |
1,542
+288
| +23% | +$15.6K | ﹤0.01% | 315 |
|
|
2021
Q4 | $69K | Buy |
1,254
+785
| +167% | +$40.8K | ﹤0.01% | 333 |
|
|
2021
Q3 | $22K | Hold |
469
| – | – | ﹤0.01% | 415 |
|
|
2021
Q2 | $23K | Sell |
469
-524
| -53% | -$25.2K | ﹤0.01% | 388 |
|
|
2021
Q1 | $44K | Buy |
993
+82
| +9% | +$3.72K | ﹤0.01% | 364 |
|
|
2020
Q4 | $42K | Buy |
+911
| New | +$41.8K | ﹤0.01% | 301 |
|
|
2016
Q3 | – | Sell |
-4,118
| Closed | -$223K | – | 221 |
|
|
2016
Q2 | $223K | Sell |
4,118
-165
| -4% | -$8.69K | ﹤0.01% | 212 |
|
|
2016
Q1 | $217K | Sell |
4,283
-876
| -17% | -$43.6K | ﹤0.01% | 210 |
|
|
2015
Q4 | $260K | Buy |
5,159
+17
| +0.3% | +$867 | ﹤0.01% | 217 |
|
|
2015
Q3 | $248K | Sell |
5,142
-1,674
| -25% | -$87.1K | ﹤0.01% | 215 |
|
|
2015
Q2 | $355K | Buy |
6,816
+618
| +10% | +$34.8K | ﹤0.01% | 199 |
|
|
2015
Q1 | $358K | Buy |
6,198
+348
| +6% | +$20K | ﹤0.01% | 201 |
|
|
2014
Q4 | $313K | Buy |
5,850
+89
| +2% | +$4.98K | ﹤0.01% | 208 |
|
|
2014
Q3 | $331K | Sell |
5,761
-35
| -0.6% | -$2.15K | ﹤0.01% | 204 |
|
|
2014
Q2 | $387K | Sell |
5,796
-10,057
| -63% | -$681K | ﹤0.01% | 196 |
|
|
2014
Q1 | $1.06M | Sell |
15,853
-1,018
| -6% | -$68.8K | 0.01% | 152 |
|
|
2013
Q4 | $1.13M | Sell |
16,871
-261
| -2% | -$16.9K | 0.01% | 152 |
|
|
2013
Q3 | $1.07M | Sell |
17,132
-1,729
| -9% | -$111K | 0.01% | 146 |
|
|
2013
Q2 | $1.18M | Buy |
+18,861
| New | +$1.2M | 0.01% | 137 |
|
Other funds holding GSK
JEST
Jones Financial Companies's GSK Position: Q1 2026 in Review
Jones Financial Companies increased its GSK (GSK) stake by 46% in Q1 2026, buying an estimated $3.83M and bringing the position to 223,097 shares worth $12M. The position accounts for 0.01% of the portfolio, ranked #764.
Jones Financial Companies first reported a position in GSK in Q2 2013 and has held it in 34 quarters since. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Jones Financial Companies held 223,097 shares of GSK worth $12M as of Q1 2026.
- Jones Financial Companies bought 70,725 GSK shares in Q1 2026, an estimated $3.83M.
- GSK made up 0.01% of Jones Financial Companies's portfolio in Q1 2026, its #764 holding.
- Jones Financial Companies first reported a position in GSK in Q2 2013 and has held it in 34 quarters since.
- 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.